Study: Treating Chronic Prostatitis / Chronic Pelvic Pain Syndrome
A clinical development is being trialled for the treatment of Chronic Prostatitis (CP) / Chronic Pelvic Pain Syndrome (CPPS).
The potential treatment is an anti-necrosis innovative drug to treat inflammatory and degenerative disease developed by a start-up pharmaceutical company Sironax. It is under Phase 1b period trial now which is a multicentre, randomised, double-blinded, placebo-controlled study to evaluate safety and efficacy of the treatment in CP/CPPS patients.
The study treatment will be taken two times per day (BID) for 28 days relative to the placebo group, and approximately 60 eligible patients will be randomly assigned at a 1:1 ratio to receive the treatment or the placebo.
The trial now is recruiting in Sydney, Melbourne and Brisbane, and is already registered on the ANZCTR (Australian New Zealand Clinical Trials Registry), trial ID number SIR365-AU-102.
The participating sites and respective Principal Investigators (PI) details are as follows:
- Australian Clinical Trials (NSW) – Professor Henry Woo
- Princess Alexandra Hospital (QLD) – Associate Professor Eric Chung
- Emeritus Research Sydney (NSW) – Professor Paul Bird
- Emeritus Research Melbourne (VIC) – Dr Deon Smith
- Cabrini Malvern Hospital (VIC) – Professor Mark Frydenberg
- Taylor Square Private Clinic (NSW) – Dr Robert Finlayson
- Barwon Health (VIC) – Mr Richard Grills
- Frankston Pain Management (VIC) – Dr Murray Taverner
Currently, there is a lack of clear evidence for proven effective treatment for CP/CPPS. USANZ Members are encouraged to consider this as another treatment option for this patient population.